NanoGhosts develops a drug targeting platform utilizing nanovesicles derived from mesenchymal stem cell membranes, which possess natural tropism to cancer and inflammation sites. This technology enables precise delivery of therapeutics to tumor microenvironments, enhancing treatment efficacy while minimizing off-target effects.
Funding
$6.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current drug delivery methods often lack precision, leading to off-target effects and reduced efficacy, particularly in cancer treatment. This lack of targeted delivery limits the therapeutic potential of many drugs and can result in significant side effects for patients.
Solution
NanoGhosts develops a drug-targeting platform based on nanovesicles derived from mesenchymal stem cell (MSC) membranes. These nanovesicles, termed Nano-Ghosts (NGs), possess inherent tropism towards cancer and inflammation sites, enabling targeted delivery of therapeutic payloads. The NGs can infiltrate both inter- and intracellular niches within the tumor microenvironment, enhancing drug concentration at the site of action while minimizing exposure to healthy tissues. This approach aims to improve treatment efficacy and reduce adverse effects associated with conventional drug delivery methods.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing targeted therapies for cancer and inflammatory diseases.
Features
- Nanovesicles derived from MSC membranes for targeted drug delivery.
- Natural tropism to cancer and inflammation sites.
- Ability to infiltrate inter- and intracellular niches.
- Versatile loading capacity for various therapeutic agents.